Red tide research points to cystic fibrosis therapy

Scientists at MIT have synthesized red tide toxin in what could be a significant advance toward developing new therapies to treat cystic fibrosis. Their goal was to determine the chemical machinery at work in developing the toxins which create red tide. Synthesizing brevetoxin and related compounds pointed to a potential new approach in cystic fibrosis. Brevenal acts as an antagonist to brevetoxin.

"It's very potent in what's called 'mucus movement,'" said MIT's Timothy Jamison. "That's the golden term in cystic fibrosis, from what I understand." 

- read the report from The News-Press

Suggested Articles

Compass' CD137 agonist cleared large tumors in mice that other I-O agents had failed to treat. It's advancing the drug into phase 1 human trials.

UPMC researchers are planning clinical trials of a COVID-19 vaccine that uses pieces of the virus' spike protein to create immunity.

Treating mice with niacin increased the number of immune cells in glioblastomas, reducing tumor size and extending survival.